Paravalvular Leak Closure and Valve-in-Valve Interventions — A Fluoroscopy Protocol for Radiation Dose Optimization

Introduction

Paravalvular leak closure and valve-in-valve (ViV) interventions have transformed the management of prosthetic valve dysfunction, offering minimally invasive alternatives to high-risk redo surgery. These transcatheter procedures, however, demand exceptional precision: operators must navigate tortuous trajectories, align prosthetic valves within degenerated surgical bioprostheses, and deploy occluders or transcatheter heart valves (THVs) with sub-millimetre accuracy. The consequence is prolonged fluoroscopy time, extensive cine angiography, and steep C-arm angulation—all of which drive radiation exposure well above standard diagnostic coronary angiography levels.

For interventional cardiologists, radiographers, and cath lab administrators, understanding how to optimize fluoroscopy while maintaining procedural safety is not optional. The stochastic risks of ionizing radiation—cataracts, thyroid malignancy, and left-sided brain tumours—are well documented in operators performing high-volume structural work. For patients, particularly those requiring multiple staged procedures, cumulative skin dose can approach deterministic thresholds. This article presents a comprehensive, evidence-based fluoroscopy protocol for paravalvular leak closure radiation dose optimization, integrating projection selection, exposure parameter modulation, echocardiographic fusion guidance, and scatter protection with SATPRO bismuth drapes.

Anatomical challenges in paravalvular and valve-in-valve interventions

Paravalvular leak anatomy and access considerations

Paravalvular defects arise from incomplete apposition between the surgical sewing ring and native annular tissue, creating irregular, often crescentic channels that may be single or multiple. The location of the leak dictates the optimal fluoroscopic projection: mitral PVLs are typically approached via transseptal puncture and require RAO caudal (30°/20°) or LAO cranial (45°/20°) views to profile the defect perpendicular to the X-ray beam. Aortic PVLs demand co-planar or three-cusp overlap views to align the defect with the delivery sheath trajectory.

The irregular geometry of PVLs necessitates repeated angiographic runs to confirm wire passage, sheath stability, and occluder positioning. Each cine acquisition at steep angulation increases the paravalvular leak closure radiation dose disproportionately because the X-ray beam traverses greater thoracic tissue depth. Operators must balance the need for anatomical clarity against the ALARA principle—keeping exposure as low as reasonably achievable without compromising safety.

Valve-in-valve sizing and alignment complexity

Valve-in-valve implantation—whether aortic (ViV), mitral (ViV), or tricuspid (ViR)—requires precise measurement of the internal diameter of the failed surgical bioprosthesis, assessment of leaflet calcification, and prediction of neo-commissural alignment. Fluoroscopy guides transseptal or transfemoral access, wire traversal, balloon valvuloplasty (if performed), and final THV deployment. The procedure often involves multiple angiographic runs to confirm coronary patency, assess paravalvular regurgitation, and rule out conduction disturbance.

In mitral valve-in-valve procedures, the transseptal trajectory and the need to avoid left ventricular outflow tract (LVOT) obstruction add considerable fluoroscopy time. Operators frequently switch between AP, RAO, and steep LAO projections to confirm coaxial alignment. These transitions, while clinically necessary, contribute to elevated cumulative air kerma if not managed with pulsed fluoroscopy and tight collimation.

Projection optimization for dose reduction

Shallow angles and co-planar views

The single most effective strategy for reducing paravalvular leak closure radiation dose is projection optimization. Shallow angulation minimizes the path length of the X-ray beam through the thorax, reducing both entrance skin dose and scatter generation. For mitral PVL closure, the standard working angles of RAO 30°/caudal 20° and LAO 45°/cranial 20° should be reserved for critical deployment phases only. During wire traversal and sheath manipulation, operators should default to pure AP (0°) or shallow RAO (10°), which provide sufficient spatial information while cutting beam attenuation by 30–40%.

For aortic PVLs, co-planar views—where the X-ray beam is aligned parallel to the plane of the aortic annulus—reduce the need for multiple steep projections. Three-cusp overlap views, achieved by subtle rotation (typically LAO 10–20°/cranial 15–25°), allow simultaneous visualization of all three commissures, minimizing the number of confirmatory cine runs. The principle is simple: every degree of angulation avoided is a measurable reduction in patient dose.

Valve-in-valve projection strategy

Valve-in-valve procedures benefit from a projection minimization protocol. During transseptal puncture and wire traversal, AP or shallow RAO views suffice. Steep LAO (60–90°) and cranial/caudal angulation should be reserved for two specific moments: (1) confirming coaxial THV alignment before deployment, and (2) assessing final valve function and coronary patency. All intermediate steps—balloon sizing, pre-dilation, and sheath advancement—should be performed under pulsed fluoroscopy in neutral or shallow angles.

The use of roadmapping further reduces the need for repeated contrast injections. By storing a reference fluoroscopy loop from an initial angiographic run, operators can navigate wires and sheaths against a static anatomical map, eliminating multiple subsequent cine acquisitions. Roadmapping is particularly valuable during transseptal puncture for mitral ViV, where the exact trajectory from inferior vena cava to fossa ovalis can be planned from a single loop.

Exposure parameters and pulsed fluoroscopy

Adult exposure settings

Standard adult cardiac catheterization protocols use continuous fluoroscopy at 15–30 frames per second (fps), with cine acquisition at 15 fps. For structural interventions, this default is excessive. The protocol recommends pulsed fluoroscopy at 3.75–7.5 fps for all non-critical phases of PVL closure and ViV implantation. At 3.75 fps, temporal resolution remains adequate for wire and sheath visualization while reducing dose rate by 50–75% compared with 15 fps continuous mode.

For cine acquisition, the standard 70–90 kV and 100–300 mA range should be modulated based on patient body habitus. In non-obese adults (BMI < 30), 75–90 kV with 100–300 mA provides diagnostic image quality. In obese patients (BMI > 35), the automatic exposure control (AEC) system will drive kV upward to 95–120 kV and mA to 300–750 mA. While AEC is necessary to penetrate adipose tissue, operators can mitigate the dose penalty by:

• Activating copper spectral filtration (0.3–0.9 mm Cu) to harden the beam and reduce low-energy scatter.
• Using last-image hold instead of cine for procedural pauses and equipment exchanges.
• Limiting cine runs to < 5 seconds per acquisition, with a mandatory 30-second pause before the next run.

Obesity-specific protocols

Obese patients undergoing PVL closure or ViV present a dual challenge: increased beam attenuation and elevated scatter generation. The AEC-driven increase in kV and mA raises operator exposure significantly, particularly to the left side of the body (nearest the X-ray tube in typical LAO projections). The protocol mandates SATPRO bismuth scatter drapes placed over the patient's torso and upper abdomen during all obese cases. These drapes attenuate scattered X-rays at the source, reducing operator hand dose by up to 60% and body dose by 40%.

Additionally, obese patients should have the detector positioned as close to the chest wall as anatomically possible. Inverse square law physics means that every 10 cm of increased source-to-image distance (SID) requires a 44% increase in exposure to maintain signal-to-noise ratio. Positioning the detector within 15 cm of the skin surface is a zero-cost dose reduction strategy.

TEE and ICE fusion guidance

3D TEE as the primary imaging modality

The most impactful innovation in reducing paravalvular leak closure radiation dose has been the integration of real-time three-dimensional transoesophageal echocardiography (3D TEE) with fluoroscopy. In experienced centres, 3D TEE provides superior anatomical detail of PVL defects, prosthetic valve frames, and surrounding structures compared with fluoroscopy alone. When TEE is used as the primary guidance modality, fluoroscopy is relegated to a confirmatory role—used only for wire traversal through the arterial system and final device release.

For mitral PVL closure, 3D TEE allows direct visualization of the defect location (typically at the 9–11 o'clock position for mitral annular dehiscence), real-time wire traversal, and immediate assessment of occluder seating. The X-ray beam is needed only for the initial transseptal puncture and final device deployment confirmation. Studies have shown that TEE-dominant protocols reduce fluoroscopy time by 35–50% and air kerma by 40–60% compared with fluoroscopy-only approaches.

Intracardiac echocardiography (ICE) integration

Intracardiac echocardiography (ICE) offers an alternative for patients who cannot tolerate general anaesthesia for TEE. Modern ICE catheters provide high-resolution imaging of the interatrial septum, mitral annulus, and aortic root from intracardiac vantage points. While ICE does not match the panoramic field of view of 3D TEE, it eliminates the need for repeated angiographic runs to confirm wire position and defect alignment.

ICE-fluoroscopy fusion systems, now available on several cath lab platforms, overlay ICE-derived anatomical landmarks onto live fluoroscopy. This fusion allows operators to navigate with the low-dose precision of ICE while retaining the spatial orientation of fluoroscopy. For tricuspid valve-in-valve (ViR) procedures, where fluoroscopic landmarks are poor and TEE may be challenging due to far-field imaging, ICE fusion has become the standard of care.

Scatter mitigation with SATPRO protection

Source-based scatter attenuation

Scatter radiation—not the primary beam—poses the greatest occupational hazard in structural interventions. During PVL closure and ViV implantation, the X-ray beam interacts with the thoracic skeleton, prosthetic valve metal, and contrast-filled cardiac chambers, generating a 360° scatter field. The operator, positioned on the patient's right side for femoral access, receives the highest scatter dose when the tube is in LAO projection (the most common working angle for mitral procedures).

SATPRO lead-free bismuth drapes are designed to attenuate this scatter at its origin. Draped over the patient's torso, abdomen, and upper thighs, these flexible shields contain bismuth oxide particles suspended in a polymer matrix, providing attenuation equivalent to 0.5 mm lead without the weight or toxicity. For PVL closure, the drape should cover:

• The entire chest wall from clavicles to xiphoid process.
• The upper abdomen, where lateral scatter from the diaphragm and liver is significant.
• The groin access site, to protect against backscatter from the femoral region.

Clinical studies demonstrate that SATPRO drapes reduce operator hand dose by 55–65% during structural procedures and lower patient entrance dose by 15–20% through backscatter reduction.

Shielding configuration for specific procedures

For mitral PVL closure via transseptal access, the operator stands on the patient's right side, exposed to left-sided scatter. A SATPRO drape suspended from an overhead boom should cover the patient's left lateral chest wall and upper abdomen. An additional sterile drape placed over the right lower chest wall protects the assistant and anaesthesia team.

For aortic ViV via transfemoral access, the primary scatter vector is posterior and left lateral. A full-torso SATPRO drape, combined with a ceiling-suspended lead acrylic shield positioned between the operator and the patient, creates a multi-layered defence. The protocol emphasizes that personal protective equipment (lead aprons, thyroid shields, and lead glasses) remains mandatory regardless of patient draping—SATPRO reduces the scatter load, but does not eliminate it.

Special populations and protocol adaptations

Adult and geriatric patients

The majority of PVL and ViV patients are adults over 65 years, often with multiple comorbidities including obesity, chronic kidney disease, and prior sternotomy. For this population, the standard protocol applies: pulsed fluoroscopy at 3.75–7.5 fps, TEE-dominant guidance, shallow angles where possible, and SATPRO draping for all cases. Particular attention should be paid to contrast-induced nephropathy prevention, as these patients require multiple angiographic runs. The SATMED Contrast Media Calculator provides patient-specific volume limits based on eGFR and body surface area.

Obesity protocol summary

Pediatric considerations

Pure pediatric PVL closure is rare, as most pediatric valve replacements are homografts or autografts with low PVL incidence. However, the principles of dose reduction are directly transferable from pediatric congenital protocols. For any pediatric patient under 20 kg, the anti-scatter grid must be removed (reducing dose by 30–50%), and spectral filtration should be minimized. Micro-collimation to the cardiac silhouette only, combined with low-frame-rate DSA (1–3 fps), ensures ALARA compliance in younger patients.

Dose monitoring and quality assurance

Systematic dose monitoring is essential for any programme performing high-volume structural interventions. Every PVL closure and ViV case should generate a dose report including: total fluoroscopy time, number and duration of cine runs, cumulative air kerma (K_a,r), kerma-area product (PKA), and peak skin dose estimate. These data should be reviewed at weekly multidisciplinary meetings, with outliers (> 5 Gy air kerma) triggering mandatory case review.

Operator feedback loops are equally important. Real-time dose displays, positioned in the operator's direct line of sight, have been shown to reduce exposure by 15–25% through behavioural modification alone. Annual personal dosimetry review should track left wrist, thyroid, and whole-body exposure, with action levels set at 50% of national regulatory limits. Programmes that combine dose monitoring, feedback, and standardized protocols report sustained reductions in median procedural dose of 30–40% over 12 months.

Further reading